Skip to main content

Table 5 Induction of anti-Tat cross-clade Abs after immunization in vaccinees negative at baseline for any anti-Tat Abs

From: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial

HIV clades

n

%

C

5

9.8

D

7

13.7

A

4

7.8

C + D

12

23.5

C + A

1

2.0

D + A

7

13.7

C + D + A

15

29.4

Total

51

100.0

  1. Sera from 51 vaccinees negative at baseline also for anti-Tat Abs against C, D and A clades were tested between week 12 and week 24 after immunization with the B-clade Tat protein. All patients mounted anti-Tat Ab responses against A, C, and/or D clade